Sold as Zorbtive. Every FDA application for this active ingredient.
As of Nov 16, 2026, FDA lists 1 application for Somatropin Recombinant (sold as Zorbtive), first approved Dec 1, 2003, with 0 new uses approved and 0 published complete response letters.
| A Phase III Clinical Study of Jinpei Growth Hormone Injection in the Treatment of Short Stature Children With Small for Gestational Age (SGA)Small for Gestational Age · Changchun GeneScience Pharmaceutical Co., Ltd. | Phase 3 | Not yet recruiting | Sep 25, 2026 |
| Phase IV Study of rhGH Injection in Adult Short Bowel SyndromeShort Bowel Syndrome (SBS) in Adults · Changchun GeneScience Pharmaceutical Co., Ltd. | Phase 4 | Recruiting | Jul 8, 2026 |
| Effects of Recombinant Human Growth Hormone in Elderly Patients With Moderate to Severe Acute Brain Injury (GH-ABI-RCT)Acute Brain Injuries, Moderate to Severe Traumatic Brain Injury · Anhui Provincial Hospital | Phase 4 | Not yet recruiting | Mar 19, 2026 |
| A Study (Phase 1b/2) of GenSci134 in Children With Idiopathic Short Stature (ISS)Idiopathic Short Stature · Changchun GeneScience Pharmaceutical Co., Ltd. | Phase 1 / Phase 2 | Not yet recruiting | Mar 4, 2026 |
| A Study of GenSci134 in Children With Growth Hormone Deficiency (PGHD)Pediatric Growth Hormone Deficiency · Changchun GeneScience Pharmaceutical Co., Ltd. | Phase 1 / Phase 2 | Not yet recruiting | Mar 4, 2026 |
| Growth Hormone and Dehydroepiandrosterone Role in Vitro FertilizationInfertility, Infertility (IVF Patients) · Beni-Suef University | Phase 2 / Phase 3 | Recruiting | Jan 7, 2026 |
| The Efficacy and Safety of Inpegsomatropin Injection in Children With Short Stature Born Small for Gestational AgeSmall for Gestational Age · Xiamen Amoytop Biotech Co., Ltd. | Phase 3 | Recruiting | Dec 30, 2025 |
| A Phase II Study of PEG-rhGH Injection for Short Children Born Small for Gestational Age: Efficacy, Safety, and PharmacokineticsShort Stature Children Born Small for Gestational Age (SGA) · Changchun GeneScience Pharmaceutical Co., Ltd. | Phase 2 | Recruiting | Dec 3, 2025 |
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| Dec 1, 2003 | ZorbtiveBLA 21597 · TYPE 6 | Emd Serono | 0 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA